Tissue engineering intravascular stent and preparation method thereof
By designing tissue-engineered vascular stents with double-layer or triple-layer tubular structures, combining highly elastic materials and biologically active functions, the problem of unsatisfactory and non-degradable mechanical properties of existing small-diameter artificial vascular stents is solved, and the mechanics matching with natural vascular are achieved Performance and regeneration of neovascular tissue.
Patent Information
- Application Number
- CN202411252245.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-03
AI Technical Summary
Existing small-diameter artificial blood vessels are prone to thrombosis and endometrial hyperplasia after implantation, and their mechanical properties are not ideal and they cannot effectively match natural blood vessels, resulting in poor long-term patency and the material is undegradable, which cannot induce the regeneration of neovascular tissue.
Tissue-engineered vascular stents with a bilayer or triple-layer tubular structure, the inner layer contains poly(sebacic acid-polyethylene glycol) ester and polycaprolactone, and the outer layer contains poly(sebacic acid-polyethylene glycol) ester and polylevolactate and polycaprolactone are added to the electrospinning film layer, combined with highly elastic poly(sebacic acid-polyethylene glycol) esters and biodegradable materials such as polycaprolactone and levolactate. Bioactive materials such as vascular endothelial growth factor and heparin form a multilayer structure with good mechanical elasticity.
The mechanical properties matching natural blood vessels are achieved, which reduces adverse mechanical stimulation after implantation, promotes the formation of neovascular tissue, improves hemocompatibility and anticoagulation properties, and ensures the complete regeneration of vascular tissue.
Smart Images

Figure HDA0005032784220000011 
Figure HDA0005032784220000021 
Figure HDA0005032784220000022
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of vascular tissue engineering, and in particular relates to a tissue engineering vascular stent and a preparation method thereof. Background Art
[0002] Small-caliber vascular repair is a common clinical situation. For acute or critically ill patients, surgical treatment is often required, among which vascular replacement or bypass transplantation is the main method. At present, the small-caliber vascular grafts used in clinical practice are mainly autologous blood vessels, such as saphenous vein, internal mammary artery, etc., and commercial small-caliber artificial blood vessels are still blank. This is because artificial blood vessels are prone to thrombosis and intimal hyperplasia after implantation, and have poor long-term patency. Traditional artificial blood vessels are mainly made of non-degradable materials, which cause many side effects after implantation. Moreover, because they are non-degradable, they cannot induce reasonable regeneration of new blood vessel tissue. In the long run, it is difficult to fundamentally solve the problem. With the development of tissue engineering technology, tissue engineering vascular stents have become a new way to solve this problem. Vascular repair has changed from traditional vascular "replacement" to new blood vessel "regeneration", that is, the diseased blood vessels are replaced by suitable tissue engineering vascular stents. Vascular stents not only provide temporary support for blood flow, but also induce cell growth and promote the formation of new tissues. With the slow degradation of the stent and the formation of new tissues, the stent is finally replaced by new and healthy new blood vessel tissues, achieving complete regeneration of vascular tissues.
[0003] There are many reasons for the failure of artificial blood vessel transplantation, one of which is that the mechanical properties of artificial blood vessels are not ideal, that is, the mechanical matching between artificial blood vessels and natural blood vessels is poor, which is mainly related to the matrix material of artificial blood vessels. On the other hand, transplantation failure is also related to the lack of biological activity on the surface of artificial blood vessel stents. Poor material surface properties are prone to cause adverse blood reactions and lead to coagulation. Therefore, an ideal tissue engineering vascular stent needs to be organically combined in many aspects such as stent materials, stent structures, and stent surface functionalization to achieve coordination and unity. Traditional tissue engineering vascular stents, such as Chinese patent CN 107296979A, disclose a tissue engineering nanofiber vascular stent composed of PLCL and degradable polymer materials. Due to material limitations, the vascular stent performs poorly in mechanical properties (poor tensile stress-strain properties) and is difficult to achieve the mechanical elasticity of natural blood vessels. Summary of the invention
[0004] In view of this, the object of the present invention is to provide a tissue engineering vascular stent and a preparation method thereof. The tissue engineering vascular stent of the present invention has good mechanical elasticity, a stress-strain curve close to that of a rabbit carotid artery, and has mechanical properties that are well matched with natural blood vessels.
[0005] The present invention provides a tissue engineering vascular stent, which is a double-layer tubular structure or a three-layer tubular structure; the double-layer tubular structure comprises an inner layer and an outer layer; the inner layer contains poly (sebacic acid-polyethylene glycol) ester and polycaprolactone; the outer layer contains poly (sebacic acid-polyethylene glycol) ester and poly-L-lactic acid;
[0006] The three-layer tubular structure comprises a double-layer tubular structure and an electrostatic spinning membrane layer on the outer surface of the double-layer tubular structure, wherein the electrostatic spinning membrane layer contains polycaprolactone.
[0007] Preferably, the mass ratio of polycaprolactone to poly(sebacic acid-polyethylene glycol) ester in the inner layer is 0.2 to 2:1.
[0008] Preferably, the inner layer further contains poly(sebacic acid-citric acid-L-cysteine-glycerol) ester.
[0009] Preferably, the mass ratio of poly(sebacic acid-citric acid-L-cysteine-propylene glycol) ester to poly(sebacic acid-polyethylene glycol) ester in the inner layer is 0 to 0.8:1, and is not 0.
[0010] Preferably, the inner surface of the inner layer is also grafted with a bioactive material, and the bioactive material includes vascular endothelial growth factor and / or heparin.
[0011] Preferably, the thickness of the inner layer is 20-80% of the total thickness of the tissue engineering vascular stent.
[0012] Preferably, the mass ratio of poly-L-lactic acid to poly(sebacic acid-polyethylene glycol) ester in the outer layer is 0.05 to 1:1.
[0013] Preferably, the electrospinning membrane layer further contains poly(sebacic acid-polyethylene glycol) ester, and the mass ratio of polycaprolactone to poly(sebacic acid-polyethylene glycol) ester in the electrospinning membrane layer is 0.5 to 100:1.
[0014] The present invention also provides a method for preparing the tissue engineering vascular stent described in the above technical solution, comprising the following steps:
[0015] Performing a first electrostatic spinning on a first polymer organic solution containing poly(sebacate-polyethylene glycol) ester and polycaprolactone to obtain a PPS / PCL composite electrostatic spinning tube;
[0016] The second polymer organic solution containing poly (sebacic acid-polyethylene glycol) ester and poly (L-lactic acid) is used to prepare a PPS / PLLA composite porous structure tube by a thermally induced phase separation method;
[0017] The PPS / PCL composite electrospun tube was used as the inner tube and the PPS / PLLA composite porous structure tube was used as the outer tube, and the two tubes were nested to obtain a tissue engineering vascular scaffold with a double-layer tubular structure.
[0018] On the outer surface of the tissue engineering vascular stent with a double-layer tubular structure, a third polymer organic solution containing polycaprolactone is used for second electrospinning to obtain a tissue engineering vascular stent with a three-layer tubular structure.
[0019] Preferably, the mass concentration of the polymer in the first polymer organic solution is 5-20%.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The present invention provides a tissue engineering vascular stent, which is a double-layer tubular structure or a three-layer tubular structure; the double-layer tubular structure includes an inner layer and an outer layer; the inner layer contains poly (sebacate-polyethylene glycol) ester and polycaprolactone; the outer layer contains poly (sebacate-polyethylene glycol) ester and poly-L-lactic acid; the three-layer tubular structure includes a double-layer tubular structure and an electrostatic spinning membrane layer on the outer surface of the double-layer tubular structure, and the electrostatic spinning membrane layer contains polycaprolactone. The tissue engineering vascular stent of the present invention uses highly elastic poly (sebacate-polyethylene glycol) ester (PPS) as a supporting material, and the obtained stent has good mechanical elasticity and mechanical properties matching natural blood vessels, which can greatly reduce the adverse mechanical stimulation of the stent to the host blood vessels after implantation in the body.
[0022] The stent materials used in the present invention, poly (sebacic acid-polyethylene glycol) ester (PPS), poly (sebacic acid-citric acid-L-cysteine-glycerol) ester (PGSCC), polycaprolactone (PCL) and poly L-lactic acid (PLLA) are all biodegradable materials, and the obtained tissue engineering vascular stent has good biocompatibility and suitable biodegradability. The tissue engineering vascular stent of the present invention is a multi-layer tubular structure and has a microscopic biomimetic (porous) structure, which is conducive to inducing the formation of new blood vessel tissue.
[0023] Furthermore, the functional material poly(sebacic acid-citrate-L-cysteine-propylene glycol) ester (PGSCC) is introduced into the inner layer of the tissue engineering vascular stent of the present invention. PGSCC contains a large number of active functional groups -COOH and -SH, which is convenient for bioactive functional modification and is beneficial to improving the blood compatibility and endothelialization efficiency of the stent. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0025] Figure 1 The uniaxial tensile stress-strain curves of the inner layer PPS / PCL composite electrospun tube (m-60PPS) of the vascular stent obtained in Example 1 and the pure PCL electrospun tube obtained in Comparative Example 1, wherein (a) is the tensile curve in the axial direction, and (b) is the tensile curve in the circumferential direction;
[0026] Figure 2 The static water contact angle test results of the inner layer PPS / PCL composite electrospun tube (m-60PPS) of the vascular stent obtained in Example 1 and the pure PCL electrospun tube obtained in Comparative Example 1;
[0027] Figure 3 The whole blood clotting time test results of several fiber membranes, wherein m-60PPS / 20PGSCC and m-60PPS / 20PGSCC-Heparin respectively represent the blank membrane and the membrane after chemically grafting heparin of the inner layer PPS / PCL / PGSCC composite electrospun membrane of the vascular stent obtained in Example 2, m-60PPS represents the inner layer PPS / PCL composite electrospun membrane of the vascular stent obtained in Example 1, and TCPS is a polystyrene tissue culture plate;
[0028] Figure 4 The macroscopic picture of the three-layer structure vascular stent obtained in Example 2 and the microscopic morphology obtained by SEM observation; (a) is a physical picture of the double-layer tube obtained by combining the inner tube and the middle tube; (b) is a physical picture of the three-layer structure blood vessel obtained by covering the outside of the double-layer tube in (a) with a layer of electrospun PCL; (c) is the SEM picture of the three-layer structure blood vessel in (b). DETAILED DESCRIPTION
[0029] The present invention provides a tissue engineering vascular stent, which is a double-layer tubular structure or a three-layer tubular structure;
[0030] The double-layer tubular structure comprises an inner layer and an outer layer; the inner layer contains poly(sebacate-polyethylene glycol) ester and polycaprolactone; the outer layer contains poly(sebacate-polyethylene glycol) ester and poly-L-lactic acid;
[0031] The three-layer tubular structure comprises a double-layer tubular structure and an electrostatic spinning membrane layer on the outer surface of the double-layer tubular structure, wherein the electrostatic spinning membrane layer contains polycaprolactone.
[0032] In the present invention, unless otherwise specified, the materials and equipment used are commercially available products in the art.
[0033] In the present invention, the wall thickness of the tissue engineering vascular scaffold is preferably 0.1 to 3 mm.
[0034] In the present invention, the poly (sebacic acid-polyethylene glycol) ester (PPS) is a highly elastic biodegradable polyester elastic material with super high elasticity and super strong stretchability, and has good biocompatibility and biodegradability. It is a structural material with excellent comprehensive performance and is suitable as a support material for the stent. The preparation method of the poly (sebacic acid-polyethylene glycol) ester can refer to Chinese patent CN 111892703 A. The weight average molecular weight of the polyethylene glycol used to prepare the poly (sebacic acid-polyethylene glycol) ester is preferably 50 to 400 g·mol -1 .
[0035] In the present invention, the weight average molecular weight (Mw) of the poly (sebacic acid-polyethylene glycol) ester (PPS) is preferably 5×10 4 ~100×10 4 g·mol -1 , more preferably 25×10 4 ~100×10 4 g·mol -1 .
[0036] In the present invention, the mass ratio of polycaprolactone (PCL) to poly(sebacate-polyethylene glycol) ester (PPS) in the inner layer is preferably 0.2 to 2:1, more preferably 2 to 3:3. The present invention uses highly elastic PPS as the main material, and the obtained stent has good mechanical elasticity and mechanical properties matching those of natural blood vessels, which can greatly reduce the adverse mechanical stimulation of the stent to the host blood vessels after implantation in the body.
[0037] In the present invention, the weight average molecular weight of the polycaprolactone (PCL) is preferably 4×10 4 ~20×10 4 g·mol -1 .
[0038] In the present invention, the inner layer preferably further contains poly (sebacic acid-citric acid-L-cysteine-glycerol) ester (PGSCC). PGSCC has good elasticity, biocompatibility and biodegradability, carries a large number of active functional groups -COOH and -SH, has reactivity, is easy to carry out functional modification, and is an ideal functional medium material. The preparation method of the poly (sebacic acid-citric acid-L-cysteine-glycerol) ester can refer to Chinese patent CN 114479037A. The present invention can use PGSCC to modify the inner layer of the stent for biological activity, such as anticoagulant modification and endothelialization modification, which can increase the biological activity of the stent.
[0039] In the present invention, the weight average molecular weight of the poly (sebacic acid-citric acid-L-cysteine-propylene glycol) (PGSCC) is preferably 2×10 4 ~50×104 g·mol -1 .
[0040] In the present invention, the mass ratio of the poly(sebacic acid-citric acid-L-cysteine-glycerol) ester (PGSCC) to the poly(sebacic acid-polyethylene glycol) ester (PPS) in the inner layer is preferably 0 to 0.8:1, and is not 0, and is more preferably 1:3.
[0041] In the present invention, the inner surface of the inner layer is preferably further grafted with a bioactive material, and the bioactive material preferably includes vascular endothelial growth factor (VEGF) and / or heparin (anticoagulant molecule).
[0042] In the present invention, the inner layer is preferably a composite electrospun fiber membrane having a nanofiber or micron fiber structure and good mechanical elasticity, and is the main layer of the stent.
[0043] In the present invention, the inner diameter of the inner layer is preferably 2 mm, the wall thickness is preferably 0.5 mm, and the thickness of the inner layer is preferably 20-80% of the total thickness of the tissue engineering vascular stent, more preferably 32%.
[0044] In the present invention, the mass ratio of poly-L-lactic acid (PLLA) to poly(sebacate) (PPS) in the outer layer is preferably 0.05 to 1:1, more preferably 1:4. The outer layer material of the present invention contains PLLA and PPS, and a connected porous structure is formed by compounding PLLA and PPS.
[0045] In the present invention, the outer layer is preferably a composite stent of PPS and PLLA prepared by thermally induced phase separation, having a macroporous structure interconnected with each other, a pore size preferably of 1 to 200 μm, good compression elasticity, and distributed on the outside of the innermost layer of the stent; the thickness of the outer layer is preferably 20 to 80% of the total thickness of the tissue engineering vascular stent.
[0046] In the present invention, the thickness of the electrospinning membrane layer on the outer surface of the double-layer tubular structure is preferably 0-40% of the total thickness of the tissue engineering vascular stent, and has a nanofiber or micron fiber structure.
[0047] In the present invention, the electrospinning membrane layer on the outer surface of the double-layer tubular structure preferably also contains poly(sebacate) ester (PPS), and the mass ratio of polycaprolactone (PCL) to poly(sebacate) ester (PPS) in the electrospinning membrane layer is preferably 0.5 to 100:1, more preferably 19:1.
[0048] The present invention also provides a method for preparing the tissue engineering vascular stent described in the above technical solution, comprising the following steps:
[0049] Performing a first electrostatic spinning on a first polymer organic solution containing poly(sebacate-polyethylene glycol) ester and polycaprolactone to obtain a PPS / PCL composite electrostatic spinning tube;
[0050] The second polymer organic solution containing poly (sebacic acid-polyethylene glycol) ester and poly (L-lactic acid) is used to prepare a PPS / PLLA composite porous structure tube by a thermally induced phase separation method;
[0051] The PPS / PCL composite electrospun tube was used as the inner tube and the PPS / PLLA composite porous structure tube was used as the outer tube, and the two tubes were nested to obtain a tissue engineering vascular scaffold with a double-layer tubular structure.
[0052] On the outer surface of the tissue engineering vascular stent with a double-layer tubular structure, a third polymer organic solution containing polycaprolactone is used for second electrospinning to obtain a tissue engineering vascular stent with a three-layer tubular structure.
[0053] The present invention performs first electrostatic spinning on a first polymer organic solution containing poly(sebacate-polyethylene glycol) ester and polycaprolactone to obtain a PPS / PCL composite electrostatic spinning tube.
[0054] In the present invention, the first polymer solution preferably further contains poly(sebacic acid-citric acid-L-cysteine-glycerol) ester. The mass ratio of the poly(sebacic acid-polyethylene glycol) ester, polycaprolactone and poly(sebacic acid-citric acid-L-cysteine-glycerol) ester is preferably 3:2:1.
[0055] In the present invention, the organic solvent in the first polymer organic solution preferably includes one or more of hexafluoroisopropanol, trifluoroethanol, trifluoroacetic acid, tetrahydrofuran, acetone, chloroform, dichloromethane and N,N-dimethylformamide; the mass concentration of the polymer in the first polymer organic solution is preferably 5-20%, more preferably 8-12%, and even more preferably 10%.
[0056] In the present invention, the conditions of the first electrospinning include: the high voltage static electricity is preferably 6.5-10kV, more preferably 7kV; the wire connection distance is preferably 8-12cm, more preferably 10cm; the propulsion rate of the spinning solution is preferably 0.4-0.6mL / h, more preferably 0.5mL / h. In the first electrospinning process, the wire is preferably connected with a rotating shaft, the rotating shaft is preferably a stainless steel rod, the diameter of the stainless steel rod is preferably 2mm, and the wire connection time is preferably 4h.
[0057] In the present invention, the inner diameter of the PPS / PCL composite electrospinning tube is preferably 2 mm, and the wall thickness is preferably 0.5 mm. The inner diameter and wall thickness of the PPS / PCL composite electrospinning tube can be adjusted according to the actual size of clinical small-caliber blood vessels (less than 6 mm).
[0058] The invention uses a thermally induced phase separation method to prepare a PPS / PLLA composite porous structure tube from a second polymer organic solution containing poly (sebacic acid-polyethylene glycol) ester and poly (L-lactic acid).
[0059] In the present invention, the second polymer organic solution is preferably obtained by mixing poly(sebacate-polyethylene glycol) ester, poly(L-lactic acid) and an organic solvent under heating, the heating temperature is preferably 50-60°C, more preferably 55°C, and the heating is preferably accompanied by stirring. The organic solvent preferably includes one or more of tetrahydrofuran, 1,4-dioxane, acetone, chloroform, dichloromethane, N,N-dimethylformamide, hexafluoroisopropanol, trifluoroethanol and trifluoroacetic acid.
[0060] In the present invention, the mass concentration of the polymer in the second polymer organic solution is preferably 1 to 20%, more preferably 6 to 12%, and even more preferably 7%.
[0061] In the present invention, the mass ratio of the poly(sebacate) ester (PPS) to the poly-L-lactic acid (PLLA) is preferably 4:1.
[0062] In the present invention, the thermally induced phase separation method preferably includes the following steps: after the second polymer organic solution is poured into the mold and quenched, solvent replacement is performed to obtain a PPS / PLLA composite porous structure tube. The mold is preferably a PTFE tubular mold, the outer diameter of the core tube of the PTFE tubular mold is preferably 3mm, and the inner diameter of the sleeve is preferably 5mm. The quenching is preferably carried out in a low temperature environment, the temperature of the low temperature environment is preferably lower than -5°C, more preferably -80°C, and the quenching time is preferably 4h. The solvent replacement preferably uses deionized water, the time of the solvent replacement is preferably 2 to 3 days, and the temperature of the deionized water is preferably 4°C. In the thermally induced phase separation process, a gel is first formed by the action of PLLA, and then a porous structure is formed by the action of PPS.
[0063] The present invention adopts the thermally induced phase separation method to prepare the PPS / PLLA composite porous structure tube, which is subsequently used as the outer tube to nest the PPS / PCL composite electrospinning tube (inner tube). The outer tube is prepared in situ on the inner tube, which causes the inner tube material to be dissolved and the inner tube to be severely damaged.
[0064] In the present invention, the inner diameter of the PPS / PLLA composite porous structure tube is preferably 3 mm, and the wall thickness is preferably 1 mm.
[0065] After obtaining the PPS / PCL composite electrospinning tube and the PPS / PLLA composite porous structure tube, the present invention uses the PPS / PCL composite electrospinning tube as an inner tube and the PPS / PLLA composite porous structure tube as an outer tube, and nests them to obtain a tissue engineering vascular stent with a double-layer tubular structure.
[0066] The present invention has no special requirements for the nesting (combination) method. The PPS / PCL composite electrospinning tube and the PPS / PLLA composite porous structure tube are nested together to form an inner and outer double-layer tubular structure.
[0067] After obtaining the tissue engineering vascular stent with a double-layer tubular structure, the present invention uses a third polymer organic solution containing polycaprolactone to perform second electrospinning on the outer surface of the tissue engineering vascular stent with a double-layer tubular structure to obtain a tissue engineering vascular stent with a three-layer tubular structure.
[0068] In the present invention, the organic solvent in the third polymer organic solution preferably includes one or more of hexafluoroisopropanol, trifluoroethanol and trifluoroacetic acid. The mass concentration of the polymer in the third polymer organic solution is preferably 8-12%, more preferably 10%. The third polymer organic solution preferably further contains poly (sebacate-polyethylene glycol) ester (PPS), and the mass ratio of the polycaprolactone (PCL) to the poly (sebacate-polyethylene glycol) ester (PPS) is preferably 1-100:1, more preferably 4-19:1, and more preferably 9:1.
[0069] In the present invention, in the second electrospinning process, the tissue engineering vascular stent with a double-layer tubular structure is used as a rotating shaft to connect the wires, and an electrospinning fiber layer is formed on the outer surface of the double-layer tubular structure. The conditions of the second electrospinning include: the high voltage static electricity is preferably 6.5-15kV, more preferably 10kV; the connection distance is preferably 8-12cm, more preferably 10cm; the propulsion rate of the spinning solution is preferably 0.4-1.2mL / h, more preferably 1mL / h.
[0070] In the present invention, the preparation method preferably further comprises grafting a bioactive material on the inner surface of the inner layer, wherein the bioactive material preferably comprises vascular endothelial growth factor (VEGF) and / or heparin (anticoagulant molecule):
[0071] When the bioactive material is preferably vascular endothelial growth factor VEGF, the -NH2-rich VEGF is covalently grafted onto the PGSCC molecule by using the condensation reaction of -COOH and -NH2, and the grafting preferably includes the following steps: dissolving carbodiimide (EDC) and succinimide (HNS) with 2-(N-morpholine)ethanesulfonic acid to prepare a solution, adding them together into a centrifuge tube containing a tissue engineering vascular scaffold, so that the solution immerses the tissue engineering vascular scaffold, and then incubating at 37°C for 20 minutes, discarding the solution, washing the tissue engineering vascular scaffold 3 times with a phosphate buffer, immediately adding the VEGF solution to immerse the vascular scaffold, incubating at 4°C for 24 hours, discarding the solution, and washing the tissue engineering vascular scaffold 3 times with a phosphate buffer;
[0072] The concentration of the VEGF solution is preferably 10-1000 ng / mL, more preferably 200 ng / mL; each 1 cm long tissue engineering vascular scaffold corresponds to 0.3-3 mL of VEGF solution. The solvent of the VEGF solution is preferably phosphate buffer (pH=7.4), and the pH value of the 2-(N-morpholino)ethanesulfonic acid solution is preferably 4.5-6.5.
[0073] When the bioactive material is preferably an anticoagulant molecule heparin, the heparin molecule is modified with a mediator molecule with a double bond, and then the heparin with a double bond is covalently grafted onto the PGSCC molecule by utilizing the specific reaction of -SH with the double bond. The grafting preferably includes the following steps: dissolving the heparin with a double bond in a phosphate buffer to prepare a solution, and then adding it to a centrifuge tube containing a tissue engineering vascular scaffold, so that the heparin solution immerses the tissue engineering vascular scaffold, incubating at 4°C for 24 hours, discarding the solution, and using a phosphate buffer for 3 times;
[0074] The concentration of the heparin solution is preferably 0.02-20 mg / mL, more preferably 6 mg / mL; each 1 cm long tissue engineering vascular stent corresponds to 0.3-3 mL of heparin solution. The solvent of the heparin solution is preferably phosphate buffer (pH=7.4).
[0075] The present invention utilizes -COOH and -SH on the tissue engineering vascular stent inner layer material PGSCC to covalently graft vascular endothelial growth factor VEGF and / or anticoagulant molecule heparin to the inner layer surface of the stent to form a bioactive stent inner surface with anticoagulant and / or endothelialization promoting effects.
[0076] The tissue engineering vascular stent with a three-layer tubular structure obtained by the present invention preferably has a PPS / PCL / PGSCC composite electrospun fiber membrane tube as an inner layer, a PPS / PLLA composite porous tube as a middle layer, and a PPS / PCL composite electrospun fiber membrane tube as an outer layer.
[0077] The present invention uses poly (sebacic acid-polyethylene glycol) ester (PPS) as the main material, and biodegradable poly (sebacic acid-citrate-L-cysteine-glycerol) ester (PGSCC), polycaprolactone (PCL) and poly-L-lactic acid (PLLA) as auxiliary materials. The tissue engineering vascular scaffold is prepared by combining electrospinning and thermally induced phase separation. The scaffold has mechanical elasticity matching that of natural blood vessels, and has a double-layer or triple-layer tubular structure and a microscopic bionic porous structure.
[0078] In order to further illustrate the present invention, the tissue engineering vascular stent and the preparation method thereof provided by the present invention are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the protection scope of the present invention.
[0079] In the specific embodiments or comparative examples of the present invention, the weight average molecular weight of the poly (sebacic acid-polyethylene glycol) ester (PPS) used is 25×10 4 ~100×10 4 g·mol -1 The weight average molecular weight of polycaprolactone (PCL) is 4×10 4 ~20×10 4 g·mol -1 The weight average molecular weight of poly (sebacic acid-citric acid-L-cysteine-propylene glycol) ester (PGSCC) is 2×10 4 ~50×10 4 g·mol -1 The weight average molecular weight of poly L-lactic acid (PLLA) is 5×10 4 ~50×10 4 g·mol -1 .
[0080] Example 1
[0081] (1) PPS and PCL were dissolved in hexafluoroisopropanol at a mass ratio of 60:40 to obtain a 10% (w / v) polymer solution, which was spun at a voltage of 7 kV, a receiving distance of 10 cm, and a propulsion rate of 0.5 mL / h. The filaments were connected with a rotating stainless steel rod with a diameter of 2 mm for 4 h to obtain a PPS / PCL composite electrospinning tube with an inner diameter of 2 mm and a wall thickness of 0.5 mm;
[0082] (2) PPS and PLLA were added to tetrahydrofuran in a mass ratio of 80:20, heated and stirred at 55° C. to dissolve the materials, and a 7% (w / v) polymer solution was obtained, which was then quickly poured into a PTFE mold with a core tube outer diameter of 3 mm and a sleeve inner diameter of 5 mm, and quickly placed in a -80° C. environment for 4 h, and then taken out and transferred to 4° C. deionized water for solvent replacement, and kept for 3 days to obtain a PPS / PLLA composite porous structure tube with an inner diameter of 3 mm and a wall thickness of 1 mm, and a pore size of 5 to 30 μm;
[0083] (3) The PPS / PCL composite electrospinning tube in step (1) is used as the inner tube, and the PPS / PLLA composite porous tube in step (2) is used as the outer tube to obtain a double-layer structure tube;
[0084] (4) PCL and PPS were dissolved in hexafluoroisopropanol at a mass ratio of 19:1 to obtain a 10% (w / v) polymer solution, which was spun at a voltage of 10 kV, a receiving distance of 10 cm, and a propulsion rate of 1.0 mL / h. The double-layer structure tube in step (3) was used as a receiver, and the wire was connected in a rotating state for 5 minutes (about 50 microns thick) to obtain a three-layer structure vascular stent.
[0085] Example 2
[0086] (1) PPS, PCL, and PGSCC were dissolved in hexafluoroisopropanol at a mass ratio of 60:40:20 to obtain a 10% (w / v) polymer solution, which was spun at a voltage of 7 kV, a receiving distance of 10 cm, and a propulsion rate of 0.5 mL / h. The spinning was continued for 4 h with a rotating stainless steel rod of 2 mm in diameter to obtain a PPS / PCL / PGSCC composite electrospinning tube with an inner diameter of 2 mm and a wall thickness of 0.5 mm;
[0087] (2) PPS and PLLA were added to tetrahydrofuran in a mass ratio of 80:20, heated and stirred at 55°C to dissolve the materials to obtain a 7% (w / v) polymer solution, which was then quickly poured into a PTFE mold with a core tube outer diameter of 3 mm and a sleeve inner diameter of 5 mm, and quickly placed in a -80°C environment for 4 hours. After being taken out, it was transferred to 4°C deionized water for solvent replacement and kept for 3 days to obtain a PPS / PLLA composite porous tube with an inner diameter of 3 mm and a wall thickness of 1 mm;
[0088] (3) The PPS / PCL / PGSCC composite electrospinning tube in step (1) is used as the inner tube, and the PPS / PLLA composite porous tube in step (2) is used as the outer tube to obtain a double-layer structure tube;
[0089] (4) PCL was dissolved in hexafluoroisopropanol to obtain a 10% (w / v) polymer solution, which was spun at a voltage of 10 kV, a receiving distance of 10 cm, and a propulsion rate of 1.0 mL / h. The double-layer structure tube in step (3) was used as a receiver, and the spun wire was connected in a rotating state for 5 minutes to obtain a three-layer vascular stent;
[0090] (5) The anticoagulant molecule heparin is covalently grafted onto the inner surface of the stent to form a bioactive stent inner surface with an anticoagulant effect. Specifically, the heparin molecule is modified with a mediator molecule with a double bond, and then the heparin with a double bond is covalently grafted onto the PGSCC molecule by using the specific reaction of -SH with the double bond. The concentration of the heparin solution is 6 mg / mL, and each 1 cm long tube corresponds to 1 mL of heparin solution. Heparin is dissolved in phosphate buffer (pH = 7.4).
[0091] Example 3
[0092] (1) PPS and PCL were dissolved in hexafluoroisopropanol at a mass ratio of 60:40 to obtain a 10% (w / v) polymer solution, which was spun at a voltage of 7 kV, a receiving distance of 10 cm, and a propulsion rate of 0.5 mL / h. The filaments were connected with a rotating stainless steel rod with a diameter of 2 mm for 4 h to obtain a PPS / PCL composite electrospinning tube with an inner diameter of 2 mm and a wall thickness of 0.5 mm;
[0093] (2) PPS and PLLA were added to tetrahydrofuran in a mass ratio of 80:20, heated and stirred at 55° C. to dissolve the materials, and a 7% (w / v) polymer solution was obtained, which was then quickly poured into a PTFE mold with a core tube outer diameter of 3 mm and a sleeve inner diameter of 5 mm, and quickly placed in a -80° C. environment for 4 h, and then taken out and transferred to 4° C. deionized water for solvent replacement, and kept for 3 days to obtain a PPS / PLLA composite porous structure tube with an inner diameter of 3 mm and a wall thickness of 1 mm, and a pore size of 5 to 30 μm;
[0094] (3) The PPS / PCL composite electrospun tube in step (1) is used as the inner tube, and the PPS / PLLA composite porous tube in step (2) is used as the outer tube to obtain a double-layer vascular stent.
[0095] Comparative Example 1
[0096] PCL was dissolved in hexafluoroisopropanol to obtain a 10% (w / v) polymer solution, which was spun at a voltage of 10 kV, a receiving distance of 10 cm, and a propulsion rate of 1.0 mL / h. The solution was connected with a rotating stainless steel rod of 2 mm in diameter for 2 h to obtain a PCL electrospinning tube with an inner diameter of 2 mm and a wall thickness of 0.5 mm, which was a pure PCL vascular stent.
[0097] Figure 1The uniaxial tensile stress-strain curves of the inner layer PPS / PCL composite electrospinning tube (m-60PPS) of the vascular stent obtained in Example 1 and the pure PCL electrospinning tube obtained in Comparative Example 1 in the axial (Figure (a)) and circumferential (Figure (b)) directions are shown. The results show that under the dominance of PPS, the obtained PPS / PCL composite fiber membrane has an extremely low initial elastic modulus of 0.25±0.058MPa in the axial direction, which is close to the natural arterial tissue and much lower than the 13.56±2.323MPa of the pure PCL fiber membrane tube, indicating that the introduction of PPS makes the mechanical properties of the obtained composite fiber membrane tube significantly better; in the circumferential direction, the stress-strain curve of the PPS / PCL composite fiber membrane is very close to that of the rabbit carotid artery (Native carotid artery), indicating that it has mechanical properties that are very compatible with natural blood vessels.
[0098] Figure 2 The static water contact angle test results of the inner layer PPS / PCL composite electrospun tube (m-60PPS) of the vascular stent obtained in Example 1 and the pure PCL electrospun tube obtained in Comparative Example 1. The results show that under the dominance of PPS, the obtained PPS / PCL composite fiber membrane has better hydrophilicity than the pure PCL fiber membrane.
[0099] Figure 3 The whole blood coagulation time test results of several fiber membranes are shown in Figure 2, where m-60PPS / 20PGSCC and m-60PPS / 20PGSCC-Heparin respectively represent the blank membrane and the membrane after chemical grafting of heparin on the inner layer PPS / PCL / PGSCC composite electrospun membrane of the vascular stent obtained in Example 2, m-60PPS represents the inner layer PPS / PCL composite electrospun membrane of the vascular stent obtained in Example 1, and TCPS is a polystyrene tissue culture plate. The results show that after the PPS / PCL / PGSCC composite fiber membrane is chemically grafted with heparin, it has a significant delaying effect on the coagulation time of whole blood, indicating that it has significantly enhanced anti-coagulation performance and better blood compatibility, which solves the problem that the current materials or vascular stents have poor blood compatibility and are prone to coagulation, while the blood of the control group material coagulates very quickly.
[0100] Figure 4The macroscopic physical image of the three-layer structure vascular stent obtained in Example 2 and the microscopic morphology obtained by SEM observation; (a) is a physical image of the double-layer tube obtained by combining the inner tube and the middle tube; (b) is a physical image of the three-layer structure blood vessel obtained after the double-layer tube in (a) is covered with a layer of electrospun PCL; (c) is an SEM image of the three-layer structure blood vessel in (b), which are the outer surface, inner surface and cross section of the tube, and the local enlarged image of the inner, middle and outer three-layer structure on the cross section. The results show that the obtained three-layer structure vascular stent has a clearly layered inner, middle and outer structure, as well as a corresponding microscopic bionic porous structure.
[0101] Although the above-mentioned embodiments have made a detailed description of the present invention, they are only some embodiments of the present invention, rather than all embodiments. People can also obtain other embodiments based on the embodiments of the present invention without creative work, and these embodiments all fall within the scope of protection of the present invention.
Claims
1. A tissue engineering vascular stent, characterized in that: It is a double-layer tubular structure or a three-layer tubular structure; the double-layer tubular structure comprises an inner layer and an outer layer; the inner layer contains poly (sebacic acid-polyethylene glycol) ester and polycaprolactone; the outer layer contains poly (sebacic acid-polyethylene glycol) ester and poly-L-lactic acid; The three-layer tubular structure comprises a double-layer tubular structure and an electrostatic spinning membrane layer on the outer surface of the double-layer tubular structure, wherein the electrostatic spinning membrane layer contains polycaprolactone.
2. The tissue engineering vascular stent according to claim 1, characterized in that: The mass ratio of polycaprolactone to poly(sebacic acid-polyethylene glycol) ester in the inner layer is 0.2 to 2:
1.
3. The tissue engineering vascular stent according to claim 1 or 2, characterized in that: The inner layer also contains poly (sebacic acid-citric acid-L-cysteine-glycerol) ester.
4. The tissue engineering vascular stent according to claim 3, characterized in that: The mass ratio of poly(sebacic acid-citric acid-L-cysteine-propylene glycol) ester to poly(sebacic acid-polyethylene glycol) ester in the inner layer is 0 to 0.8:1, and is not 0.
5. The tissue engineering vascular stent according to claim 3, characterized in that: The inner surface of the inner layer is also grafted with a bioactive material, and the bioactive material includes vascular endothelial growth factor and / or heparin.
6. The tissue engineering vascular stent according to claim 1, characterized in that: The thickness of the inner layer is 20-80% of the total thickness of the tissue engineering vascular stent.
7. The tissue engineering vascular stent according to claim 1, characterized in that: The mass ratio of poly-L-lactic acid to poly(sebacic acid-polyethylene glycol) ester in the outer layer is 0.05 to 1:
1.
8. The tissue engineering vascular stent according to claim 1, characterized in that: The electrostatic spinning membrane layer also contains poly(sebacate-polyethylene glycol) ester, and the mass ratio of polycaprolactone to poly(sebacate-polyethylene glycol) ester in the electrostatic spinning membrane layer is 0.5-100:
1.
9. The method for preparing the tissue engineering vascular scaffold according to any one of claims 1 to 8, characterized in that: The following steps are involved: Performing a first electrostatic spinning on a first polymer organic solution containing poly(sebacate-polyethylene glycol) ester and polycaprolactone to obtain a PPS / PCL composite electrostatic spinning tube; The second polymer organic solution containing poly (sebacic acid-polyethylene glycol) ester and poly (L-lactic acid) is used to prepare a PPS / PLLA composite porous structure tube by a thermally induced phase separation method; The PPS / PCL composite electrospun tube was used as the inner tube and the PPS / PLLA composite porous structure tube was used as the outer tube, and the two tubes were nested to obtain a tissue engineering vascular scaffold with a double-layer tubular structure. On the outer surface of the tissue engineering vascular stent with a double-layer tubular structure, a third polymer organic solution containing polycaprolactone is used for second electrospinning to obtain a tissue engineering vascular stent with a three-layer tubular structure.
10. The preparation method according to claim 9, characterized in that: The mass concentration of the polymer in the first polymer organic solution is 5-20%.
Citation Information
Patent Citations
Tissue engineering nanofiber intravascular stent and preparation method thereof
CN107296979A
Biodegradable thermoplastic polyester elastic material and preparation method thereof
CN111892703A
Biodegradable polyester elastomer material and preparation method thereof
CN114479037A
